|
Oct 9
|
Nyxoah SA (NYXH) Q2 2024 Earnings Call Highlights: Strategic Growth and US Market Preparations
|
|
Oct 9
|
Publication relating to transparency notifications
|
|
Oct 8
|
Nyxoah Secures $27 Million to Boost U.S. Presence
|
|
Oct 7
|
Nyxoah Raises $27 Million through its At-the-Market Offering
|
|
Jul 29
|
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024
|
|
May 23
|
Nyxoah Announces Pricing of Offering
|
|
May 22
|
Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program
|
|
May 22
|
Nyxoah Announces Proposed Offering of Ordinary Shares
|
|
Mar 29
|
Information on the total number of voting rights and shares
|
|
Mar 7
|
Nyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call Transcript
|
|
Mar 5
|
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
|
|
Mar 5
|
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
|
|
Feb 29
|
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
|
|
Jan 9
|
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023
|
|
Dec 11
|
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®
|
|
Dec 8
|
Publication Relating to a Transparency Notification
|
|
Nov 12
|
Nyxoah S.A. (NASDAQ:NYXH) Q3 2023 Earnings Call Transcript
|
|
Nov 8
|
Nyxoah Reports Third Quarter 2023 Financial and Operating Results
|
|
Nov 7
|
Nyxoah to Participate in the Jefferies London Healthcare Conference
|
|
Sep 28
|
Nyxoah Announces Partnership with ResMed in Germany
|